Burns Market

DelveInsight’s ‘Burns-Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Burns historical and forecasted epidemiology as well as the Burns market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Burns market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Burns market size from 2021 to 2030. The Report also covers current Burns treatment practice, market drivers, market barriers, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2018–2030

Burns Disease Understanding and Treatment Algorithm

Burns Overview

Burn injuries are underappreciated injuries that are associated with substantial morbidity and mortality. Burn injuries, particularly severe burns, are accompanied by an immune and inflammatory response, metabolic changes, and distributive shock that can be challenging to manage and can lead to multiple organ failures. Of great importance is that the injury affects not only physical health but also the patient’s mental health and quality of life.

Burn injuries are underappreciated trauma that can affect anyone, anytime and anywhere. The injuries can be caused by friction, cold, heat, radiation, chemical, or electric sources, but most burn injuries are caused by heat from hot liquids, solids, or fire. Although all burn injuries involve tissue destruction due to energy transfer, different causes can be associated with different physiological and pathophysiological responses.

Burns Diagnosis

The determination of the severity of a burn depends on the depth of the burn and the width of the area. It is necessary to wait for 24–48 h to determine the exact burn grade, as the depth of the burn may increase due to edema and infection. The depth of the burn varies according to the type of the causative agent, the degree of temperature, and the thickness and vascularity of the affected skin area. Accurate assessment of the severity of a burn injury is paramount because it forms the basis for all subsequent treatment decisions, triage plans, and assessment of medical futility. Whenever possible, decisions about proceeding after diagnosis and screening should incorporate patient preferences and expectations about the quality of life. Optimal assessment of the severity of burn injury must involve a systematic, methodical approach, such as that described in course materials for the Advanced Trauma Life Support (ATLS) by the American College of Surgeons Committee on Trauma, Emergency Management of the Severe Burn (EMSB) by the Australian and New Zealand Burn Association, and Advanced Burn Life Support (ABLS) by the ABA.

Continued in the report…..

Burns Treatment

In the current market scenario, the standard treatment for skin burn involves medications, wound dressings, grafts and surgery. The treatment goals are to control pain, remove dead tissue, prevent infection, reduce scarring risk, and regain function. The treatment depends on the severity of the burn.

Medical treatment includes water-based treatments (Ultrasound mist therapy to clean and stimulate the wound tissue), fluids to prevent dehydration (intravenous (IV) fluids to prevent dehydration and organ failure), pain and anxiety medications (morphine and anti-anxiety medications), creams and ointments (bacitracin and silver sulfadiazine), dressings (wound dressings), and common topical antimicrobials such as silver sulfadiazine (SSD), cerium plus SSD, silver nitrate, mafenide, bacitracin, and Xeroform. Apart from the above-mentioned pharmacological treatment options, the most important management practice involves surgery. Early autografting then build on these improvements by rapidly closing excised wounds, further reducing infection risk, decreasing pain, and enabling earlier mobilization. If there are concerns about the viability or bacterial load on the wound bed and/or the patient’s stability, allografting is preferred to cover the debrided wound temporarily. Some commercially available skin substitutes are Epicel, StrataGraft, RECELL System, Split thickness skin graft, Kerecis Omega3 products, and several others.

Continued in the report…..

Burns Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Incident Cases of Burn Patients Requiring Treatment, Gender-specific Incident Cases of Treated Burn Injuries, Etiology-specific Incident Cases of Treated Burn Injuries, Severity-specific Incident Cases of Treated Burn Injuries, and Incident Cases of Hospitalized Burn Patients scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Key Findings

In 2020, total incident population of burn injuries that required medical treatment in seven major markets were reported to be 1,853,475. These cases are increasing at a CAGR of 0.56% during study period
The number of hospitalized burn cases in the seven major market is expected to increase at a CAGR of 0.59% for the study period, i.e. 2018–2030.
The estimates suggest the United States had highest incident population of burn injuries that required medical treatment with 663,010 cases in 2020 out of which the estimated cases of hospitalized burn patients in 2020 were 76,511.
According to analysis, after scald (31.4%), the fire/flame was the foremost contributing cause for burn injuries in the US, occupying 40.6% of total incident cases of treatment taking burn injuries.
Our analysis indicates that the majority of burn injury cases taking treatment are males. This is accompanied by the fact that major burn injuries occur at workplaces; thus, the burn injury cases in males are predominantly higher. There were 411,066 male and 251,944 female cases of treated burn injuries in 2020.
In 2020, the severity-specific estimated cases were 144,536, 387,198, 19,890, and 111,386 for first-degree, second-degree, third-degree, and unspecified, respectively in the United States.
Among the EU5 countries, the UK had the highest incident population of burn patients that require medical treatment with 269,423 cases, followed by France (202,721 cases) and Spain (144,584 cases) in 2020. On the other hand, Germany had the lowest incident population (122,227).
Japan had 328,255 incident cases of burn injuries requiring medical treatment in 2020, the second-highest of all other countries in 7MM.

Country-Wise Burns Epidemiology

The epidemiology segment also provides the Burns epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Burns Drug Chapters

Burns Marketed Drug

NexoBrid/KMW-1: MediWound Germany GmbH/Kaken Pharmaceutical Co., Ltd.

NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, is an easy-to-use, topically-applied product that removes eschar in 4 h without harming the surrounding healthy tissues. NexoBrid’s rapid and selective debridement alleviates the known risks associated with eschars, such as infection, eventual sepsis, wound deterioration, and consequential scarring. It allows physicians to reach an informed decision on further treatment at an earlier stage by direct visual assessment of the actual burn depth. Furthermore, it minimizes the burden associated with invasive surgical procedures, reduces the need for skin grafting and sacrifice of healthy tissue from donor sites on a patient’s body, and generally results in a more favorable overall long-term patient outcome. NexoBrid has been investigated in hundreds of patients across more than 22 countries and four continents in nine completed Phase II, Phase III, and postmarketing clinical studies. In clinical trials, the product has been referred to as “Debridase” and “Debrase.”